Cited by 91

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine

Sureshchandra, Suhas, Lewis, Sloan A., Doratt, Brianna M., Jankeel, Allen, Coimbra Ibraim, Izabela, Messaoudi, Ilhem·2021·JCI Insight

Published version of a preprint

Abstract

mRNA vaccines for SARS-CoV-2 have shown exceptional clinical efficacy, providing robust protection against severe disease. However, our understanding of transcriptional and repertoire changes following full vaccination remains incomplete. We used scRNA-Seq and functional assays to compare humoral and cellular responses to 2 doses of mRNA vaccine with responses observed in convalescent individuals with asymptomatic disease. Our analyses revealed enrichment of spike-specific B cells, activated CD4 + T cells, and robust antigen-specific polyfunctional CD4 + T cell responses following vaccination. On the other hand, although clonally expanded CD8 + T cells were observed following both vaccination and natural infection, CD8 + T cell responses were relatively weak and variable. In addition, TCR gene usage was variable, reflecting the diversity of repertoires and MHC polymorphism in the human population. Natural infection induced expansion of CD8 + T cell clones that occupy distinct clusters compared to those induced by vaccination and likely recognize a broader set of viral antigens of viral epitopes presented by the virus not seen in the mRNA vaccine. Our study highlights a coordinated adaptive immune response in which early CD4 + T cell responses facilitate the development of the B cell response and substantial expansion of effector CD8 + T cells, together capable of contributing to future recall responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.153201

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Immunological changes with SARS-CoV-2 mRNA vaccination. (A) Experimental design for the study. Blood was collected from SARS-CoV-2–naive individuals before vaccination, 2 weeks after dose 1, and 2 weeks after prime-boost vaccination (VACC group) or in SARS-CoV-2–exposed but asymptomatic individuals (CONV group) before and after convalescence. Immune phenotypes of PBMCs and antigen-specific T and B cell responses were measured using multicolor flow cytometry. Longitudinal serological responses to the vaccine were measured using ELISA and neutralization assays. Memory T and B cells from a subset of PBMC samples (n = 4/group for vaccine volunteers, n = 3/group for convalescent health care workers, matched) were profiled using scRNA-Seq at baseline (before vaccination) or after vaccination time points. (B) UMAP projection of 32,867 memory T and B cells with major subsets annotated. (C) Violin plots of key gene markers used for cluster annotations. Normalized transcript counts are shown on the y axis.
Figure 1 Immunological changes with SARS-CoV-2 mRNA vaccination. (A) Experimental design for the study. Blood was collected from SARS-CoV-2–naive individuals before vaccination, 2 weeks after dose 1, and 2 weeks after prime-boost vaccination (VACC group) or in SARS-CoV-2–exposed but asymptomatic individuals (CONV group) before and after convalescence. Immune phenotypes of PBMCs and antigen-specific T and B cell responses were measured using multicolor flow cytometry. Longitudinal serological responses to the vaccine were measured using ELISA and neutralization assays. Memory T and B cells from a subset of PBMC samples (n = 4/group for vaccine volunteers, n = 3/group for convalescent health care workers, matched) were profiled using scRNA-Seq at baseline (before vaccination) or after vaccination time points. (B) UMAP projection of 32,867 memory T and B cells with major subsets annotated. (C) Violin plots of key gene markers used for cluster annotations. Normalized transcript counts are shown on the y axis.CC BY · PubMed Central
Figure 2 B cell adaptations following SARS-CoV-2 mRNA vaccination and infection. (A) Dot plots representing expansion of spike+ cells within total CD20+ B cells in PBMCs before and after vaccination (aggregate differences at baseline, n = 5, and following vaccination, n = 8, on the left; matched differences on the right, n = 4). PBMCs were incubated with biotinylated spike protein and fluorochrome-conjugated streptavidin, surface stained, washed, and analyzed using flow cytometry. Group differences were tested using unpaired t test with Welch’s correction (left) or paired t test (right). Error bars denote medians and interquartile ranges. (B) Magnified image of B cell subsets identified using scRNA-Seq. Data include samples from all 4 groups. (C) Pie chart quantifying B cell cluster frequencies after infection and vaccination. (D) Isotype distribution of productive B cell clones in vaccinated (n = 4) and convalescent (n = 3) individuals. Isotypes were determined based on the constant region of the clone. (E) Aggregate clonal abundance following vaccination and infection. (F) Volcano plots depicting heavy chain gene usage biases following convalescence (relative to preinfection baseline) or vaccination (relative to prevaccination baseline). The x axis represents the change in gene usage, and the y axis represents P value (–log10). *P < 0.05.
Figure 2 B cell adaptations following SARS-CoV-2 mRNA vaccination and infection. (A) Dot plots representing expansion of spike+ cells within total CD20+ B cells in PBMCs before and after vaccination (aggregate differences at baseline, n = 5, and following vaccination, n = 8, on the left; matched differences on the right, n = 4). PBMCs were incubated with biotinylated spike protein and fluorochrome-conjugated streptavidin, surface stained, washed, and analyzed using flow cytometry. Group differences were tested using unpaired t test with Welch’s correction (left) or paired t test (right). Error bars denote medians and interquartile ranges. (B) Magnified image of B cell subsets identified using scRNA-Seq. Data include samples from all 4 groups. (C) Pie chart quantifying B cell cluster frequencies after infection and vaccination. (D) Isotype distribution of productive B cell clones in vaccinated (n = 4) and convalescent (n = 3) individuals. Isotypes were determined based on the constant region of the clone. (E) Aggregate clonal abundance following vaccination and infection. (F) Volcano plots depicting heavy chain gene usage biases following convalescence (relative to preinfection baseline) or vaccination (relative to prevaccination baseline). The x axis represents the change in gene usage, and the y axis represents P value (–log10). *P < 0.05.CC BY · PubMed Central
Figure 3 T cell adaptations with SARS-CoV-2 mRNA vaccination. (A) Stacked bar graph comparing the distribution of memory CD4+ and CD8+ T cells across each group, reported as percentage of total cells. (B) Clustered heatmap comparing aggregate top markers from each of the memory T cell clusters. Colors represent normalized transcript levels, ranging from low (in blue) to high (in red). (C) Gating strategy for identification of activated CD4+ and CD8+ T cells before and after vaccination. (D) Frequencies of CD38+HLA-DR+ CD4+ and CD8+ T cells following vaccination (n = 4/group). (E and F) Violin plots comparing key genes differentially expressed in (E) activated CD8+ and (F) CD8+ EM subsets either with convalescence and/or vaccination. (G) Box plot comparing exhaustion scores within CD8+ T cells with convalescence and/or vaccination. Lines indicate quartiles and median scores. (H) Polyfunctional CD4+ T cell (Th1) and (I) Th17 responses following overnight stimulation with SARS-CoV-2 spike–overlapping peptide pool, measured using intracellular cytokine staining at baseline (n = 3) and following vaccination (n = 4). (J) Secreted levels of soluble costimulatory molecule (sCD137), cytokines (IL-10, IL-6, IL-2, and IL-4), and effector molecules (granzyme A and granzyme B) in CD4+ T cells at baseline (n = 5) or following mRNA vaccination (n = 8). Two-way comparisons were tested using either paired test for matched comparisons or unpaired t test with Welch’s correction for group comparisons. Four-way comparisons were tested using 1-way ANOVA followed by Holm-Šidák multiple-hypothesis correction. Error bars denote medians and interquartile ranges. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 3 T cell adaptations with SARS-CoV-2 mRNA vaccination. (A) Stacked bar graph comparing the distribution of memory CD4+ and CD8+ T cells across each group, reported as percentage of total cells. (B) Clustered heatmap comparing aggregate top markers from each of the memory T cell clusters. Colors represent normalized transcript levels, ranging from low (in blue) to high (in red). (C) Gating strategy for identification of activated CD4+ and CD8+ T cells before and after vaccination. (D) Frequencies of CD38+HLA-DR+ CD4+ and CD8+ T cells following vaccination (n = 4/group). (E and F) Violin plots comparing key genes differentially expressed in (E) activated CD8+ and (F) CD8+ EM subsets either with convalescence and/or vaccination. (G) Box plot comparing exhaustion scores within CD8+ T cells with convalescence and/or vaccination. Lines indicate quartiles and median scores. (H) Polyfunctional CD4+ T cell (Th1) and (I) Th17 responses following overnight stimulation with SARS-CoV-2 spike–overlapping peptide pool, measured using intracellular cytokine staining at baseline (n = 3) and following vaccination (n = 4). (J) Secreted levels of soluble costimulatory molecule (sCD137), cytokines (IL-10, IL-6, IL-2, and IL-4), and effector molecules (granzyme A and granzyme B) in CD4+ T cells at baseline (n = 5) or following mRNA vaccination (n = 8). Two-way comparisons were tested using either paired test for matched comparisons or unpaired t test with Welch’s correction for group comparisons. Four-way comparisons were tested using 1-way ANOVA followed by Holm-Šidák multiple-hypothesis correction. Error bars denote medians and interquartile ranges. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure 4 Clonal expansion of T cells following SARS-CoV-2 mRNA vaccination and infection. (A) CDR3 distribution of T cell clones following vaccination (top) and infection (bottom). Arrows highlight shifts in peak CDR3 lengths. (B) Pie chart representations of distribution of T cell clone sizes following vaccination and infection. (C) Diversity profiles of T cells following vaccination (n = 4, 2 time points) and infection (n = 3, 2 time points). The y axis represents Hill diversity, interpreted as the effective number of clonotypes within the data set. (D) Clonotype tracking in 4 volunteers for 2 weeks following the second dose of mRNA vaccine. Only the top 10 clones after vaccination with evidence of clonal expansion following vaccination are highlighted. (E and F) UMAP projection of the top 10 expanded clones following (E) vaccination (each participant is highlighted) and (F) convalescence.
Figure 4 Clonal expansion of T cells following SARS-CoV-2 mRNA vaccination and infection. (A) CDR3 distribution of T cell clones following vaccination (top) and infection (bottom). Arrows highlight shifts in peak CDR3 lengths. (B) Pie chart representations of distribution of T cell clone sizes following vaccination and infection. (C) Diversity profiles of T cells following vaccination (n = 4, 2 time points) and infection (n = 3, 2 time points). The y axis represents Hill diversity, interpreted as the effective number of clonotypes within the data set. (D) Clonotype tracking in 4 volunteers for 2 weeks following the second dose of mRNA vaccine. Only the top 10 clones after vaccination with evidence of clonal expansion following vaccination are highlighted. (E and F) UMAP projection of the top 10 expanded clones following (E) vaccination (each participant is highlighted) and (F) convalescence.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 17

  1. 10.1038/s41577-021-00522-1 · DOI
  2. Thomas, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months, N Engl J Med
  3. 10.1016/j.immuni.2021.08.001 · DOI · Paper page
  4. CDC. If You Need a Second Shot. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/second-shot.html Updated October 18, 2021. Accessed November 3, 2021 · DOI
  5. Mateus J, et al. Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory [preprint]. https://doi.org/10.1101/2021.06.30.21259787 Posted on medRxiv July 5, 2021 · DOI · Paper page
  6. 10.1038/s41591-021-01329-2 · DOI · Paper page
  7. Sheikh-Mohamed S, et al. A mucosal antibody response is induced by intra-muscular SARS-CoV-2 mRNA vaccination [preprint]. https://doi.org/10.1101/2021.08.01.21261297 Posted on medRxiv August 19, 2021 · DOI
  8. Cho, Anti- SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination, Nature
  9. 10.1038/s41586-021-03738-2 · DOI · Paper page
  10. Ssemaganda A, et al. Expansion of tissue-resident CD8+ T cells and CD4+ Th17 cells in the nasal mucosa following mRNA COVID-19 vaccination [preprint]. https://doi.org/10.1101/2021.05.07.442971 Posted on bioRxiv May 9, 2021 · DOI
  11. 10.1126/sciimmunol.abf7550 · DOI
  12. 10.1038/s41590-020-0762-x · DOI · Paper page
  13. Wang, 2021, Identification of potential vaccine targets for COVID-19 by combining single-cell and bulk TCR sequencing, Clin Transl Med, 11, 10.1002/ctm2.430 · DOI
  14. Westmeier, 2020, Impaired cytotoxic CD8+ T cell response in elderly COVID-19 patients, mBio, 11, e02243, 10.1128/mBio.02243-20 · DOI
  15. 10.3389/fimmu.2021.693054 · DOI
  16. 10.1172/JCI141054 · DOI
  17. Mudd PA, et al. SARS-CoV-2 mRNA vaccination elicits robust and persistent T follicular helper cell response in humans [preprint]. https://doi.org/10.1101/2021.09.08.459485 Posted on bioRxiv September 8, 2021 · DOI

Cited by

Sorted by citations

See all 91

Metadata

Authors
Sureshchandra, S., Lewis, S. A., Doratt, B. M., Jankeel, A., Coimbra Ibraim, I., & Messaoudi, I.
Affiliations
Department of Molecular Biology and Biochemistry,
Venue
JCI Insight
Published
2021-12-22
Volume
6
Issue
24
ISSN
2379-3708
Cited by
91
References
13
Language
en
Funders
National Institutes of Health (UL1TR001414, F31 A028704)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review